CXCR4 and non-small cell lung carcinoma: Gürgen et al. tested a low-dose combination regimen consisting of Etoricoxib, plerixafor, Afatinib, and Cabozantinib in NSCLC patient-derived xenograft (PDX) models, achieving an 81% overall response rate (ORR) and 100% clinical benefit rate (CBR), even in therapy-resistant adenocarcinomas and squamous cell carcinomas lacking targetable mutations, reinforcing the importance of CXCR4 inhibition in overcoming treatment resistance (Gürgen et al., 2022).